SIPO1-AD: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Siponimod in Patients With Mild Alzheimer&Amp;#39;s Disease Dementia
Latest Information Update: 23 May 2025
At a glance
- Drugs Siponimod (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions; Proof of concept
- Acronyms SIPO1-AD
Most Recent Events
- 15 May 2025 Planned initiation date changed from 1 Nov 2024 to 1 Jul 2025.
- 17 Oct 2024 New trial record